SCHEMBL30384641

SCHEMBL30384641

Fc1c(I)ccc(Br)c1Cl

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.34
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22289786 1.00 NOTUM (0.34) NOTUMHTR2AHTR2CHTR2B
SCHEMBL30384989 0.83 NOTUM (0.40) NOTUM
SCHEMBL17711300 0.83 NOTUM (0.40) NOTUM
SCHEMBL29509555 0.77 NOTUM (0.38) NOTUMHTR2AHTR2CHTR2B
SCHEMBL17709972 0.77 NOTUM (0.38) NOTUMHTR2AHTR2CHTR2B
SCHEMBL2487490 0.77 KDM1A (0.39)
SCHEMBL23486898 0.75 NOTUM (0.37) NOTUMHTR2AHTR2CHTR2B
SCHEMBL9339526 0.75 HTR2A (0.32) HTR2AHTR2CHTR2B
SCHEMBL1507770 0.75
SCHEMBL31384112 0.75 HTR2A (0.32) NOTUMHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642778-A1 LSD1 MODULATORS Recursion Pharmaceuticals, Inc. (US) 2025-11-05 EP disclosed
US-12421211-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2025-09-23 US disclosed
US-20240368117-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-11-07 US disclosed
WO-2024141757-A1 LSD1 MODULATORS EXSCIENTIA AI LIMITED (GB) 2024-07-04 WO disclosed
US-11858912-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-01-02 US disclosed
US-20230337531-A1 NOVEL COMPOUNDS AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME LG CHEM, LTD. (KR) 2023-10-19 US disclosed
US-20230133845-A1 NOVEL HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230337531-A1 NOVEL COMPOUNDS AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME CRY1, AHR, CRY2 NOTUM 4015/4885HTR2A 659/4885HTR2C 215/4885
US-11858912-B2 Heterocyclic compounds F12, C1R, MRPL21 NOTUM 4180/4885HTR2A 3065/4885HTR2C 1893/4885
US-12421211-B2 Heterocyclic compounds F12, C1R, MRPL21 NOTUM 4180/4885HTR2A 3065/4885HTR2C 1893/4885
US-20230133845-A1 NOVEL HETEROCYCLIC COMPOUNDS F12, PM20D2, XDH NOTUM 4216/4885HTR2A 3387/4885HTR2C 2291/4885
US-20240368117-A1 HETEROCYCLIC COMPOUNDS F12, C1R, MRPL21 NOTUM 4180/4885HTR2A 3065/4885HTR2C 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.